Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
Sponsor: Guangzhou Bio-gene Technology Co., Ltd
Summary
This study is a single-arm, single-center Investigator-Initiated Trial (IIT) designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of CD19-BCMA CAR-T cells in subjects diagnosed with connective tissue diseases.
Official title: A Single-center Clinical Study to Evaluate the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
Key Details
Gender
All
Age Range
1 Year - 70 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-08-30
Completion Date
2029-08-31
Last Updated
2025-09-03
Healthy Volunteers
No
Conditions
Interventions
CAR-T
Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
Locations (1)
Dongguan Taixin Hospital
Dongguan, Guangdong, China